- Home
- TCMD vs SKYE Comparison
TCMD vs SKYE Comparison
Compare TCMD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCMD
- SKYE
- Stock Information
- Founded
- TCMD 1995
- SKYE 2012
- Country
- TCMD United States
- SKYE United States
- Employees
- TCMD N/A
- SKYE N/A
- Industry
- TCMD Medical/Dental Instruments
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TCMD Health Care
- SKYE Health Care
- Exchange
- TCMD Nasdaq
- SKYE Nasdaq
- Market Cap
- TCMD 235.5M
- SKYE 115.9M
- IPO Year
- TCMD 2016
- SKYE N/A
- Fundamental
- Price
- TCMD $9.66
- SKYE $3.67
- Analyst Decision
- TCMD Hold
- SKYE Buy
- Analyst Count
- TCMD 3
- SKYE 6
- Target Price
- TCMD $16.00
- SKYE $16.60
- AVG Volume (30 Days)
- TCMD 203.0K
- SKYE 2.2M
- Earning Date
- TCMD 08-04-2025
- SKYE 08-08-2025
- Dividend Yield
- TCMD N/A
- SKYE N/A
- EPS Growth
- TCMD N/A
- SKYE N/A
- EPS
- TCMD 0.66
- SKYE N/A
- Revenue
- TCMD $293,164,000.00
- SKYE N/A
- Revenue This Year
- TCMD $7.96
- SKYE N/A
- Revenue Next Year
- TCMD $8.53
- SKYE N/A
- P/E Ratio
- TCMD $14.68
- SKYE N/A
- Revenue Growth
- TCMD 5.96
- SKYE N/A
- 52 Week Low
- TCMD $8.61
- SKYE $1.14
- 52 Week High
- TCMD $21.10
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- TCMD 38.60
- SKYE 60.03
- Support Level
- TCMD $9.80
- SKYE $3.78
- Resistance Level
- TCMD $10.32
- SKYE $4.75
- Average True Range (ATR)
- TCMD 0.32
- SKYE 0.62
- MACD
- TCMD -0.00
- SKYE -0.05
- Stochastic Oscillator
- TCMD 5.49
- SKYE 27.80
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.